维利西呱在心力衰竭治疗中的研究进展  

Vericiguat in Treatment of Heart Failure

作　　者：居昊 吴钢[1] JU Hao;WU Gang(Department of Cardiology,Renmin Hospital of Wuhan University,Wuhan 430060,Hubei,China)

机构地区：[1]武汉大学人民医院心内科,湖北武汉430060

出　　处：《心血管病学进展》2023年第8期713-717,共5页Advances in Cardiovascular Diseases

基　　金：国家自然科学基金(82270243)。

摘　　要：全球现有6000多万人罹患慢性心力衰竭,尽管针对这类患者的药物研究不断取得突破,但射血分数降低的心力衰竭患者的死亡和住院风险仍很高。在心力衰竭发生过程中,NO-sGC-cGMP通路活性降低是疾病进展的重要机制。新型药物维利西呱直接刺激可溶性鸟苷酸环化酶,修复NO-sGC-cGMP通路,从而保护心脏,改善心力衰竭患者的症状和预后。现就维利西呱的机制及目前的应用现状做一综述。More than 60 million patients worldwide are surferred from chronic heart failure.Although drug research on heart failure patients has made a major breakthrough,the risk of death and hospitalization of heart failure patients with reduced ejection fraction is still high.In patients with heart failure,the activity of NO-sGC-cGMP pathway decreases,which does damage to the heart and blood vessels.The new drug called vericiguat directly stimulates sGC and repairs the NO-sGC-cGMP pathway to protect the heart and improve the symptoms and prognosis of patients with heart failure.Now,this article reviews the mechanism and current application status of vericiguat.

关 键 词：维利西呱 慢性心力衰竭 NO-sGC-cGMP通路 

分 类 号：R541.6[医药卫生—心血管疾病]